Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III randomized double-blind placebo-controlled study of B001 injection in AQP4-IgG positive NMOSD
CTR20241605Phase 3Active
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Jul 2024
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of B001 in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Started Jul 2024; status: active.
02
Drugs
B001
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on CTR20241605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241605.